QSAM Biosciences (QSAM Biosciences) Cash-to-Debt : 173.25 (As of Dec. 2023)

View and export this data going back to 2011. Start your Free Trial

What is QSAM Biosciences Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. QSAM Biosciences's cash to debt ratio for the quarter that ended in Dec. 2023 was 173.25.

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. Here we can see, QSAM Biosciences could pay off its debt using the cash in hand for the quarter that ended in Dec. 2023.

The historical rank and industry rank for QSAM Biosciences's Cash-to-Debt or its related term are showing as below:

QSAM' s Cash-to-Debt Range Over the Past 10 Years
Min: 0 Med: 0.09 Max: 173.25
Current: 173.25

During the past 13 years, QSAM Biosciences's highest Cash to Debt Ratio was 173.25. The lowest was 0.00. And the median was 0.09.

QSAM's Cash-to-Debt is ranked better than
81.62% of 1540 companies
in the Biotechnology industry
Industry Median: 6.525 vs QSAM: 173.25

QSAM Biosciences Cash-to-Debt Historical Data

The historical data trend for QSAM Biosciences's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

QSAM Biosciences Cash-to-Debt Chart

QSAM Biosciences Annual Data

Trend

Mar14

Mar15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

2.61

0.50

173.25

QSAM Biosciences Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Cash-to-Debt	Get a 7-Day Free Trial															0.50	106.38	48.75	55.88	173.25

Competitive Comparison of QSAM Biosciences's Cash-to-Debt

For the Biotechnology subindustry, QSAM Biosciences's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

QSAM Biosciences's Cash-to-Debt Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, QSAM Biosciences's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where QSAM Biosciences's Cash-to-Debt falls into.

QSAM Biosciences Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

QSAM Biosciences's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1.386	/	(0.008	+	0)
	=	173.25

QSAM Biosciences's Cash to Debt Ratio for the quarter that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	1.386	/	(0.008	+	0)
	=	173.25

QSAM Biosciences (OTCPK:QSAM) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

QSAM Biosciences Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of QSAM Biosciences's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

QSAM Biosciences (QSAM Biosciences) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » QSAM Biosciences Inc (OTCPK:QSAM) » Definitions » Cash-to-Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

9442 Capital of Texas Highway North, Plaza 1, Suite 500, Austin, TX, USA, 78759

Website

https://www.qsambio.com

QSAM Biosciences Inc is a clinical-stage novel radiopharmaceutical company. The company is developing treatments for bone cancer and related diseases.

Executives

Adam King	officer: Chief Financial Officer	9442 CAPITAL OF TEXAS HWY N, PLAZA 1, SUITE 500, AUSTIN TX 78759
Link Jr. Charles J	director	C/O NEWLINK GENETICS CORP., 2503 SOUTH LOOP DR., SUITE 5100, AIMES IA 50010
Adriann Sax	director	7 DORSET COURT,, EAST BRUNSWICK, NJ 08816
David Charles Link	director	2100 E 54TH STREET NORTH, SIOUX FALLS SD 57104
Douglas R Baum	director, officer: CEO & Director	5000 RAFFEE COVE, AUSTIN TX 78731-1132
C Richard Piazza	director, officer: Executive Chairman	2236 EAST MALL, SUITE 208, UNIVERSITY OF BRITISH COLUMBIA, VANCOUVER A1 V6T 1Z3
Checkmate Strategic Capital Holdings, Llc	other: Member of 13(d) 10% owner grp	595 E. COLORADO BOULEVARD, SUITE 530, PASADENA CA 91101
Checkmate Strategic Capital 2, Llc	10 percent owner, other: See Explanation of Responses	595 E. COLORADO BOULEVARD, SUITE 530, PASADENA CA 91101
Checkmate Capital Group, Llc	10 percent owner, other: Member of 13(d) 10% owner grp	595 E. COLORADO BOULEVARD, SUITE 530, PASADENA CA 91101
Charles Thomas Paschall	other: Member of 13(d) 10% owner grp	595 E. COLORADO BOULEVARD, SUITE 530, PASADENA CA 91101
Christopher M. Nelson	director, officer: General Counsel	420 ROYAL PALM WAY, SUITE #100, PALM BEACH FL 33480
Scott W. Whitney	director, other: Former Director	96 WINDSOR DRIVE, PINE BROOK NJ 07058
Kevin Bolin	director, officer: Former Chairman & CEO	1081 ROSEDALE DRIVE, ATLANTA GA 30306
Tristan Peitz	director, other: Former Director	C/O Q2POWER TECHNOLOGIES, INC., 420 ROYAL PALM WAY, #100, PALM BEACH FL 33480
Joel David Mayersohn	director	350 EAST LAS OLAS BLVD. #1150, FORT LAUDERDALE FL 33301